NCT02900716View on ClinicalTrials.gov

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions

Chronic Lymphocytic LeukemiaB-Cell Lymphoma

Interventions

DRUG

DTRMWXHS-12

DRUG

DTRM-505

DTRMWXHS-12 and everolimus

DRUG

DTRM-555

DTRMWXHS-12 and everolimus and pomalidomide

Trial Locations (6)

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

27710

Duke University Medical Center, Durham

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

85054

Mayo Clinic, Phoenix

06510

Yale Cancer Center, New Haven

All Listed Sponsors

lead

Zhejiang DTRM Biopharma

INDUSTRY

NCT02900716 - Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Biotech Hunter | Biotech Hunter